BioMedNewsBreaks – Branded Legacy Inc. (BLEG) Acquires All In Extracts LLC

Branded Legacy (OTC: BLEG), (soon to be known as Royal Enterprises Inc.), a burgeoning company in the pharmaceutical biotechnology sector, today announced its strategic acquisition of All In Extracts, a pioneering entity focused on medicinal ethnobotany. The milestone deal amplifies Branded Legacy’s focus on innovation, expansion and collaborative growth within the biotech community. “As soon as I met with the All In team, I knew something great was in the making,” said Branded Legacy CEO David Oswald. “It is a rare enough thing to find a company motivated primarily by the positive impact they can make on society. We are extremely pleased that they saw the same in us. The balance between All In and our subsidiary Royal Biotek is uncanny, from production areas where one is weak and the other is strong, to marketing and branding abilities vs inventory on hand. We even have the perfect balance of equipment in our labs with little to no overlap: their lab is exactly what our next expansion would have been, and vice versa. This is the yin and yang of mergers.”

To view the full press release, visit https://ibn.fm/NsJ2d

About Branded Legacy Inc.

Branded Legacy is a diversified holdings company focused on the biotech sector. With a commitment to excellence and innovation, Branded Legacy specializes in the development and marketing of cutting-edge products and services. The company’s diverse portfolio includes ventures in biotechnology, digital solutions and wellness products, all aimed at enhancing the quality of life for its customers. Branded Legacy’s strategic approach to growth involves identifying and integrating promising businesses and technologies that align with its mission to deliver sustainable, high-quality products and services. For more information, visit the company’s website at https://BrandedLegacy.com.

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN